NCT05528887View on ClinicalTrials.gov

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2026

Conditions
Relapsed/Refractory Hematological MalignanciesLymphomaMyelomaLeukemia
Interventions
BIOLOGICAL

Autologous CAR-T cells

D0: CAR-T cells will be infused intravenously.

DRUG

Fludarabine

D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.

DRUG

Cyclophosphamide

D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.

Trial Locations (1)

315101

RECRUITING

The Affiliated People's Hospital of Ningbo University, Ningbo

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

The Affiliated People's Hospital of Ningbo University

OTHER_GOV